NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Forecast, Price & News

$4.46

-0.14 (-3.04%)

(As of 10/2/2023 ET)

Compare

Today's Range: $4.43
▼
$4.60
50-Day Range: $4.60
▼
$7.82
52-Week Range: $4.43
▼
$14.97

Volume: 2.39 million shs
Average Volume: 2.18 million shs
Market Capitalization: $1.29 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.13

AbCellera Biologics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 418.5% Upside
$23.13 Price Target
Short Interest: Bearish
12.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.51) to ($0.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

767th out of 969 stocks

Pharmaceutical Preparations Industry

370th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
AbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.13, AbCellera Biologics has a forecasted upside of 418.5% from its current price of $4.46.
Amount of Analyst Coverage
AbCellera Biologics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.80% of the float of AbCellera Biologics has been sold short.
Short Interest Ratio / Days to Cover
AbCellera Biologics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
Change versus previous month
Short interest in AbCellera Biologics has recently decreased by 4.17%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
AbCellera Biologics does not currently pay a dividend.
Dividend Growth
AbCellera Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABCL.

2.0

News and Social Media Coverage

News Sentiment
AbCellera Biologics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.
Search Interest
Only 19 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.
MarketBeat Follows
22 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.39% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.51) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbCellera Biologics is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbCellera Biologics is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AbCellera Biologics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Price History

30 days | 90 days | 365 days | Advanced Chart

ABCL Stock News Headlines

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ABCL)

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

September 27, 2023 | benzinga.com

Board Member of AbCellera Biologics Purchased $98K In Stock

October 2, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 25, 2023 | seekingalpha.com

AbCellera's Clinical Carousel: High Risk, Higher Stakes

September 20, 2023 | finance.yahoo.com

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

September 15, 2023 | benzinga.com

AbCellera Biologics Chief Operating Officer Trades Company's Stock

September 14, 2023 | finance.yahoo.com

Insider Buying: Veronique Lecault Acquires 20,000 Shares of AbCellera Biologics Inc

August 31, 2023 | finance.yahoo.com

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

October 2, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

August 31, 2023 | msn.com

Benchmark Maintains AbCellera Biologics (ABCL) Buy Recommendation

August 31, 2023 | markets.businessinsider.com

Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects

August 31, 2023 | finance.yahoo.com

10 Stocks That Could 10X Over the Next 10 Years

August 19, 2023 | finance.yahoo.com

Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 4.7% drop adds to a year losses

August 19, 2023 | finance.yahoo.com

Billionaire Stan Druckenmiller’s Small-Cap Stock Picks

August 10, 2023 | benzinga.com

AbCellera Biologics Board Member Makes $177K Stock Purchase

August 5, 2023 | msn.com

Goldman Sachs Maintains AbCellera Biologics (ABCL) Buy Recommendation

August 4, 2023 | finance.yahoo.com

Q2 2023 Abcellera Biologics Inc Earnings Call

August 4, 2023 | finance.yahoo.com

AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript

August 3, 2023 | seekingalpha.com

AbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | finance.yahoo.com

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

August 3, 2023 | finance.yahoo.com

AbCellera Reports Q2 2023 Business Results

August 2, 2023 | benzinga.com

Earnings Preview: AbCellera Biologics

July 25, 2023 | finance.yahoo.com

Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?

July 24, 2023 | stockhouse.com

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

July 19, 2023 | msn.com

AbCellera Biologics: Promising Platform, But Watch-And-Wait Approach Advised

July 14, 2023 | seekingalpha.com

Why did AbCellera Biologics stock dip today? AI-driven rally cools

July 6, 2023 | finance.yahoo.com

AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023

See More Headlines

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings: 8/03/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABCL
CUSIP: N/A
CIK: 1703057
Web: www.abcellera.com
Phone: 604-559-9005
Fax: N/A
Employees: 590
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $23.13
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +419.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $158.52 million
Net Margins: -50.91%
Pretax Margin: -48.89%
Return on Equity: -6.05%
Return on Assets: -4.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.83
Quick Ratio: 7.83

Sales & Book Value

Annual Sales: $485.42 million
Price / Sales: 2.65
Cash Flow: $0.65 per share
Price / Cash Flow: 6.87
Book Value: $4.31 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 289,360,000
Free Float: 195,460,000
Market Cap: $1.29 billion
Optionable: Not Optionable
Beta: 0.09

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Carl L.G. Hansen Ph.D. (Age 48)
CEO, Pres & Chairperson
Comp: $711.47k

Mr. Andrew Booth M.B.A. (Age 49)
Chief Financial Officer
Comp: $642.42k

Dr. Veronique Lecault Ph.D. (Age 38)
COO & Director
Comp: $645.07k

Mr. Tryn T. Stimart Esq. (Age 53)
J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
Comp: $644.4k

Mr. Neil Aubuchon M.B.A. (Age 53)
Chief Commercial Officer
Comp: $684.81k

Marcie Thiessen CPA
CGA, Sr. Director of Fin. & Accounting

Dr. Ester Falconer Ph.D. (Age 48)
Chief Technology Officer

Josephine Hellschlienger Ph.D.
Mang. of Investor Relations

Ms. Tiffany Chiu B.Sc.
Ph.D., VP of Communications

Alexandra Weirich M.Sc.
Mang. of Marketing & Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.
What is AbCellera Biologics' stock price forecast for 2023?: 8 analysts have issued 12 month price targets for AbCellera Biologics' stock. Their ABCL share price forecasts range from $12.00 to $34.00. On average, they predict the company's stock price to reach $23.13 in the next year. This suggests a possible upside of 419.7% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.
How have ABCL shares performed in 2023?: AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 56.1% and is now trading at $4.45.
View the best growth stocks for 2023 here.
When is AbCellera Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ABCL earnings forecast.
How were AbCellera Biologics' earnings last quarter?: AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The company had revenue of $10.10 million for the quarter, compared to analyst estimates of $12.38 million. AbCellera Biologics had a negative net margin of 50.91% and a negative trailing twelve-month return on equity of 6.05%. The company's revenue was down 78.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) EPS.
What ETFs hold AbCellera Biologics' stock?: ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?: (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.
What is AbCellera Biologics' stock symbol?: AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."
How do I buy shares of AbCellera Biologics?: Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AbCellera Biologics' stock price today?: One share of ABCL stock can currently be purchased for approximately $4.45.
How much money does AbCellera Biologics make?: AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.29 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.27) on an earnings per share basis.
How many employees does AbCellera Biologics have?: The company employs 590 workers across the globe.
How can I contact AbCellera Biologics?: The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial